Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AG 01 - A&G Pharmaceutical

Next Previous
X
Search
Drug Profile

AG 01 - A&G Pharmaceutical

Alternative Names: AG-01 - A&G Pharmaceutical

Latest Information Update: 16 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator A&G Pharmaceutical
  • Developer A&G Pharmaceutical; University of Maryland Greenbaum Cancer Center
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action PC cell-derived growth factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mesothelioma; Non-small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 05 Dec 2023 Pharmacodynamics data from a preclinical trial in Triple negative breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 14 Apr 2023 US FDA approves IND application for AG 01 in Solid tumours before April 2023
  • 14 Feb 2022 Phase-I clinical trials in Mesothelioma (Second-line therapy or greater, Refractory metastatic disease, Late-stage disease) in USA (IV) (NCT05627960)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top